Status:
RECRUITING
Treatment Responses of Early Syphilis to Ceftriaxone Plus Doxycycline
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Early Syphilis
Eligibility:
All Genders
20+ years
Phase:
PHASE4
Brief Summary
In a prospective study investigating the prevalence of STIs among at-risk PLWH, the prevalence of Chlamydia trachomatis and N. gonorrhoeae was 24.7% and 12.1%, respectively. Surprisingly, the study fo...
Detailed Description
Enrolled criteria: 1. PLWH aged 20 years or more 2. PLWH with early syphilis (i.e. primary, secondary, or early latent syphilis), confirmed by a positive rapid plasma reagin (RPR) titer with a reacti...
Eligibility Criteria
Inclusion
- PLWH aged 20 years or more
- PLWH with early syphilis (i.e. primary, secondary, or early latent syphilis), confirmed by a positive rapid plasma reagin (RPR) titer with a reactive Treponema pallidum particle agglutination (TPPA) assay.
- PLWH has provided informed consent
Exclusion
- PLWH with RPR titers of less than 4
- Exposure to antibiotics with activity against T. pallidum, such as penicillins, third- generation cephems, doxycycline, or macrolides, within the preceding 4 weeks
- A known or suspected infection other than syphilis requiring additional treatment with an antimicrobial active against T. pallidum
- A history of intolerance to penicillin, ceftriaxone, or doxycycline
- Pregnancy
Key Trial Info
Start Date :
March 10 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 31 2026
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05980871
Start Date
March 10 2023
End Date
January 31 2026
Last Update
November 18 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kuan-Yin Lin
Taipei, Taiwan, Taiwan, 110